<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27828643</article-id>
      <article-id pub-id-type="pmc">5087228</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20164301</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fixed drug eruption by etoricoxib confirmed by patch test<xref ref-type="fn" rid="fn1">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>de Sousa</surname>
            <given-names>Aline Soares</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cardoso</surname>
            <given-names>Jos&#xE9; Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gouveia</surname>
            <given-names>Miguel Pinto</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gameiro</surname>
            <given-names>Ana Rita</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Teixeira</surname>
            <given-names>Vera Barreto</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gon&#xE7;alo</surname>
            <given-names>Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Complexo Hospitalar Padre Bento de Guarulhos &#x2013; Guarulhos
(SP), Brazil</aff>
      <aff id="aff2"><label>2</label>Hospital Universit&#xE1;rio de Coimbra &#x2013; Coimbra,
Portugal</aff>
      <author-notes>
        <corresp id="c1">Mailing address: Aline Soares de Sousa, Rua Fonseca Pinto, 3000-075
&#x2013; 10&#xBA; andar setor de dermatologia - Coimbra, Portugal. E-mail:
<email>dra.aliness@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2016</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2016</year>
      </pub-date>
      <volume>91</volume>
      <issue>5</issue>
      <fpage>652</fpage>
      <lpage>654</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2016 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2016</copyright-year>
        <copyright-holder>Anais Brasileiros de Dermatologia</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Non-steroidal, anti-inflammatory drugs, followed by antibiotics, are the main
causes of fixed drug eruption. They provoke one or several round erythematous or
bullous lesions that recur in the same place after taking the causative
medication. A positive patch test on residual, lesional skin can replace
satisfactorily oral reintroduction. We describe the case of a 74-year-old woman
with numerous, rounded, erythematous lesions on the trunk and recurrent
blistering on the fifth right-hand finger, which developed a few hours after
taking etoricoxib. Lesional patch testing with etoricoxib was positive and
reproduced the typical pattern of a fixed drug eruption upon histopathology. We
emphasize the specific reactivity of the etoricoxib patch test, and the capacity
to reproduce the histologic pattern of the reaction.</p>
      </abstract>
      <kwd-group>
        <kwd>Drug eruptions</kwd>
        <kwd>Histology</kwd>
        <kwd>Patch tests</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by one
or multiple skin lesions that begin one to two weeks after the first exposure to the
drug. These lesions present as erythematous and edematous round plaques, sometimes
with a central blister. They can be found anywhere on the body but favor the oral
mucosa, lips and genitalia. With subsequent exposures, lesions reactivate within 24
hours and then fade several days, often leaving a residual, post-inflammatory,
grey-brown pigmentation. After a further administration of the culprit drug, lesions
appear at the same locations but may also emerge at new locations. In the presence
of numerous lesions, it is termed generalized FDE and may be difficult to
differentiate from erythema multiforme major, Stevens-Johnson Syndrome and toxic
epidermal necrolysis, with which it shares histopathological findings.<sup><xref rid="r1" ref-type="bibr">1</xref></sup></p>
      <p>The drugs most frequently associated with FDE are non-steroid, anti-inflammatory
drugs (NSAIDs), followed by antibiotics.<sup><xref rid="r2" ref-type="bibr">2</xref></sup></p>
      <p>Oral drug rechallenge is considered the gold standard diagnostic test, but even with
low doses, the culprit drug may cause simultaneous reactivation of all lesions and
create new ones, which is impracticable in patients with numerous bullous
lesions.</p>
      <p>Alternatively, patch testing on a previously involved site may be the preferred
test,<sup><xref rid="r3" ref-type="bibr">3</xref></sup>, especially in cases
induced by NSAIDs.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> Patch testing
should be performed six weeks after the acute eruption, with lesions in remission.
The culprit drug and related drugs (if possible) are applied under occlusion for 24
hours in test chambers or in open tests, in both non-lesional skin on the back and
in previously involved areas. Readings should be performed 24 and 48 hours
thereafter. The test is considered positive if there is erythema and pruritus,
infiltration or more intense reactions.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup> In highly suspicious cases entailing negative patch
tests, it is advisable to repeat the patch test on the affected area with the
suspected allergen at the same or higher concentrations (up to 20%), under
occlusion. If tests remain negative, oral rechallenge under strict surveillance is
an option. Rechallenge tests are considered positive if recurrence of inflammatory
signs in residual lesions occurs within the following 24hours.<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref></sup></p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>We report the case of a 74-year-old female patient who regularly consumed multiple
drugs, with no previous adverse reactions. She was observed in the emergency room
for a violaceous plaque of 5cm in diameter with central blistering on the medial
side of the fifth right-hand finger, as well as multiple, smaller, round
erythematous lesions on the upper back and lateral side of the arms.</p>
      <p>These skin lesions appeared less than 12 hours after taking etoricoxib
(Exxiv<sup>&#xAE;</sup>) for joint pain. The patient described a similar
episode two months beforehand, involving only the right-hand finger. She was treated
with betamethasone cream and fusidic acid, leading to clinical improvement.</p>
      <p>Six weeks later, with the cutaneous reaction in remission and some residual macular
pigmented lesions, patch testing was performed, applying the allergens from the
European baseline series and a series of 12 NSAIDs on non-lesional skin, involving
occlusion for 48 hours in Finn Chambers. Additionally, in ill-defined residual
hyperpigmented areas (two on the upper back, and one on the right-hand finger), we
applied etoricoxib 10% in vaseline using Finn chambers with occlusion periods of 24
hours. As we did not have pure etoricoxib, an Exxiv<sup>&#xAE;</sup> 90mg pill was
grinded into fine powder and manipulated in vaseline to obtain a 10% concentration
of the active drug. Readings performed after 24 hours revealed a positive reaction
to etoricoxib only in previously involved areas (<xref ref-type="fig" rid="f1">Figures 1</xref> and <xref ref-type="fig" rid="f2">2</xref>). No positive
reaction to celecoxib (Celebrex<sup>&#xAE;</sup>) 10% was observed in lesional or
normal skin.</p>
      <p>
        <fig id="f1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Positive patch test at 24 hours with erythema and infiltration of the
patch test area on residual lesions, and negative patch test when
performed on non-involved skin (red arrow)</p>
          </caption>
          <graphic xlink:href="abd-91-05-0652-g01"/>
        </fig>
      </p>
      <p>
        <fig id="f2" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Highlight of reactivation of the skin lesion in the fifth right-hand
finger after contact test</p>
          </caption>
          <graphic xlink:href="abd-91-05-0652-g02"/>
        </fig>
      </p>
      <p>A cutaneous biopsy in a positive test area located on the upper back at 24 hours
revealed spongiosis, lymphocyte exocytosis and marked vacuolization of the basal
cell layer, with some apoptotic keratinocytes, associated with a lymphocytic dermal
infiltrate, with some intravascular neutrophils, consistent with the diagnosis of
FDE (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p>
      <p>
        <fig id="f3" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Dermal infiltrate, with some intravascular neutrophils at a lower
magnification. Spongiosis and lymphocytic exocytosis with vacuolization
of the basal cell layer as well as apoptotic keratinocytes, at a higher
magnification</p>
          </caption>
          <graphic xlink:href="abd-91-05-0652-g03"/>
        </fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>We present the case of a polymedicated, elderly patient with etoricoxib-induced FDE.
Diagnosis was based on the typical clinical presentation and confirmed by a positive
lesional patch test that reproduced the typical histopathology of FDE. Etoricoxib is
a newly developed NSAID, a cyclo-oxygenase 2 selective inhibitor, rarely described
as the culprit drug in FDE, which makes this a peculiar case.<sup><xref rid="r7" ref-type="bibr">7</xref></sup></p>
      <p>In agreement with previous studies, patch testing on lesional skin was useful to
confirm etoricoxib as the culprit drug in this FDE case.<sup><xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r2" ref-type="bibr">2</xref></sup> It should be
highlighted that patch testing must be performed on residual lesional areas, where
epidermal CD8+ memory T lymphocytes are retained for many years<sup><xref rid="r6" ref-type="bibr">6</xref></sup>. This explains the exclusive
reactivity of these locations facing oral rechallenge and probably facilitates
reactivation after cutaneous exposure due to patch testing.<sup><xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup></p>
      <p>Histologically, after oral reactivation, there is a lichenoid reaction with pigment
incontinence; in more exuberant lesions, there is a significant hydropic
degeneration of basal cells with dyskeratotic cells in the epidermis, a dermal
lymphocytic infiltrate and dermal melanophages.<sup><xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup> Similar features were observed in our patient's
positive lesional patch test, demonstrating that in cutaneous adverse drug
reactions, the histology of patch tests can reproduce many aspects of the acute
reaction.<sup><xref rid="r8" ref-type="bibr">8</xref></sup></p>
      <p>Since the presence or absence of cross-reactions can also be evaluated by lesional
patch testing, these data can be important in recommending alternative safe drugs.
In FDE induced by etoricoxib, patients can safely use the other coxib with a
different chemical <bold>structure. The</bold> absence of cross-reactivity with
celecoxib has also been confirmed by lesional patch testing, as in our case (<xref ref-type="fig" rid="f4">Figure 4</xref>).<sup><xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r9" ref-type="bibr">9</xref></sup></p>
      <p>
        <fig id="f4" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Etoricoxib and Celecoxib chemical structure</p>
          </caption>
          <graphic xlink:href="abd-91-05-0652-g04"/>
        </fig>
      </p>
      <p>With an aging population, the growing consumption of medication and the
commercialization of new drugs by the pharmaceutical industry, there is an increased
incidence in adverse cutaneous drug reactions. Etiologic confirmation of FDE is
sometimes hard, particularly in polymedicated patients. After identification of the
culprit drug, patients should be given a list of drugs to avoid, to prevent new and
more severe episodes of cutaneous adverse drug reactions.<sup><xref rid="r10" ref-type="bibr">10</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflict of Interest: None</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None</p>
      </fn>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Work performed at the Hospital Universit&#xE1;rio de Coimbra &#x2013; Coimbra,
Portugal.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Revuz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Allonore</surname>
              <given-names>LV</given-names>
            </name>
          </person-group>
          <chapter-title>Drug Reactions</chapter-title>
          <person-group person-group-type="author">
            <name>
              <surname>Bolognia</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Jorizzo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Schaffer</surname>
              <given-names>JV</given-names>
            </name>
          </person-group>
          <source>Dermatology</source>
          <year>2012</year>
          <edition>3rd ed</edition>
          <publisher-loc>St Louis</publisher-loc>
          <publisher-name>Elsevier</publisher-name>
          <fpage>345</fpage>
          <lpage>347</lpage>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andrade</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Brinca</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alo</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Patch testing in fixed drug eruptions - a 20 year
review</article-title>
          <source>Contact Dermatitis</source>
          <year>2011</year>
          <volume>65</volume>
          <fpage>195</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="pmid">21702758</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gon&#xE7;alo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fernandes</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Robalo-Cordeiro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Figueiredo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Topical provocation in fixed drug eruption from nonsteroidal
anti-inflammatory drugs</article-title>
          <source>Exogenous Dermatology</source>
          <year>2002</year>
          <volume>1</volume>
          <fpage>81</fpage>
          <lpage>86</lpage>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barbaud</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bruynzeel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bircher</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <collab>European Society of Contact Dermatitis</collab>
          </person-group>
          <article-title>Guidelines for performing skin tests with drugs in the
investigation of cutaneous adverse drug reactions</article-title>
          <source>Contact Dermatitis</source>
          <year>2001</year>
          <volume>45</volume>
          <fpage>321</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="pmid">11846746</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Gon&#xE7;alo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bruynzeel</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <chapter-title>Patch testing in drug eruptions</chapter-title>
          <person-group person-group-type="author">
            <name>
              <surname>Johansen</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Frosch</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Lepoittevin</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <source>Contact Dermatitis</source>
          <year>2011</year>
          <edition>5th ed</edition>
          <publisher-loc>Berlin-Heidelberg</publisher-loc>
          <publisher-name>Springer-Verlag</publisher-name>
          <fpage>475</fpage>
          <lpage>492</lpage>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>UpToDateR.com</collab>
          </person-group>
          <comment>Internet</comment>
          <person-group person-group-type="author">
            <name>
              <surname>Shiohara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mockenhaupt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Corona</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <source>Fixed drug eruption. UpToDateR</source>
          <date-in-citation content-type="access-date">2014 Jan 09</date-in-citation>
          <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com">http://www.uptodate.com</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andrade</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alo</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Fixed drug eruption caused by etoricoxib - 2 cases confirmed by
patch testing</article-title>
          <source>Contact Dermatitis</source>
          <year>2011</year>
          <volume>64</volume>
          <fpage>118</fpage>
          <lpage>120</lpage>
          <pub-id pub-id-type="pmid">21210830</pub-id>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gon&#xE7;alo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cardoso</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Coutinho</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Garneiro</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Tellechea</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Histopathology of patch tests depends on the pattern of CADR, not
on the culprit drug</article-title>
          <source>Contact Dermatitis</source>
          <year>2014</year>
          <volume>70</volume>
          <fpage>36</fpage>
          <lpage>37</lpage>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Figueiredo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Fixed drug eruption to piroxicam Positive patch tests with
cross-sensitivity to tenoxicam</article-title>
          <source>J Dermatolog Treat</source>
          <year>1999</year>
          <volume>10</volume>
          <fpage>209</fpage>
          <lpage>212</lpage>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Varalda</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Motta</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Adverse reactions to nonsteroidal
anti-inflammatory</article-title>
          <source>Rev. bras. alerg. imunopatol</source>
          <year>2009</year>
          <volume>32</volume>
          <fpage>27</fpage>
          <lpage>34</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
